Compare SOBR & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOBR | RDHL |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.8M |
| IPO Year | 2008 | 2012 |
| Metric | SOBR | RDHL |
|---|---|---|
| Price | $0.57 | $0.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 174.4K | 22.5K |
| Earning Date | 04-10-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.55 | N/A |
| EPS | ★ 6.12 | N/A |
| Revenue | ★ $437,421.00 | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.10 | ★ N/A |
| Revenue Growth | ★ 105.62 | N/A |
| 52 Week Low | $0.48 | $0.71 |
| 52 Week High | $5.27 | $3.31 |
| Indicator | SOBR | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 42.96 | 41.73 |
| Support Level | $0.51 | $0.79 |
| Resistance Level | $1.03 | $0.89 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 28.01 | 51.31 |
Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending ea4 software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.